We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





AACC Survey Finds Nearly Half of All US Labs Still Do Not Have Supplies for Running COVID-19 Tests

By LabMedica International staff writers
Posted on 30 Jul 2020
A new survey of clinical laboratories in the US has found that nearly half of all responding labs still do not have the supplies they need to run COVID-19 tests.

The survey was conducted by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) which has presented its findings to the White House Coronavirus Task Force, calling on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.

As coronavirus cases in the US soar, the country’s labs have continued to work tirelessly to ramp up testing to help bring the pandemic under control. More...
However, even though US labs are now performing an average of 800,000 COVID-19 tests per day, which is double the average daily number of tests performed in late May, labs in many areas are reporting delays of up to a week in getting test results back to patients. These delays render testing essentially useless in acute patient care and in contact tracing. The main cause of these crippling delays is the persistent shortage of testing and other essential supplies.

AACC conducted a survey to determine the full extent of these supply shortages and how they are changing as the pandemic progresses, in the hopes that this information can help guide the federal government’s response. AACC surveyed clinical labs across the US about this issue during three different time periods: May 1-24, June 1-5, and June 24-July 6. The results showed a troubling trend, namely that supply shortages have persisted over the last few months. In May, 58% of all labs surveyed reported problems getting supplies, a figure that only decreased to 46% by early July. Even more worrying was a rise in the number of labs that are unable to process all requested COVID-19 tests within a week because of supply shortages. In early July, 25% of respondents reported this problem, an uptick from 21% of respondents in May.

The specific supplies that labs have the most difficulty obtaining are COVID-19 test kits and the reagents, or chemicals, used to perform these tests. As of early July, 58% of labs reported problems getting test kits, while 46% reported problems getting reagents. 38% of labs also still reported problems getting the nasal swabs used to obtain patient samples for COVID-19 testing. In fact, out of all the items that respondents had difficulty obtaining in May, personal protective equipment (PPE) is the only one that was not in short supply in late June/early July. While 32% of labs had problems getting PPE in May, only 4% reported having this issue in the most recent survey.

“We at AACC are deeply concerned that clinical labs continue to struggle with obtaining the supplies needed to meet our nation’s COVID-19 diagnostic testing demands,” said AACC President Dr. Carmen Wiley. “While we recognize the difficulty the federal government is encountering with this pandemic, we urge the Task Force to use the data from AACC’s survey as a jumping off point to investigate these ongoing shortages, and to use the authority of the federal government to obtain and allocate these vital supplies.”

Related Links:
American Association for Clinical Chemistry (AACC)


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.